@article {10.3844/ajbbsp.2026.22.02.025,
article_type = {journal},
title = {Effect of Metformin Treatment on Inflammatory Factors and Gut Microbial Diversity in Patients with Type II Diabetes Mellitus},
author = {Tong, Lei and Zhang, Jingjing and Yue, Li Xiao and Chen, Li and Wang, Meng Xiang},
volume = {22},
number = {2},
year = {2026},
month = {Jul},
pages = {25-1},
doi = {10.3844/ajbbsp.2026.22.02.025},
url = {https://thescipub.com/abstract/ajbbsp.2026.22.02.025},
abstract = {With the persistent rise in the prevalence of Type 2 Diabetes Mellitus (T2DM), traditional treatment evaluations have primarily focused on glycemic control, often overlooking the multidimensional effects of medications. As a first-line therapeutic agent, the anti-inflammatory effects and gut microbiota regulation mechanisms of metformin remain incompletely elucidated. This prospective cohort study established a metformin treatment group and a T2DM control group not receiving metformin. Using metagenomics technology, we analyzed the effects of metformin therapy on serum inflammatory markers (interleukin-6, tumor necrosis factor-α, high-sensitivity C-reactive protein) and gut microbiota diversity in T2DM patients. Results showed that after 12 weeks of intervention, the treatment group exhibited significantly reduced inflammatory markers (IL-6 ↓25.4%, TNF-α ↓18.9%, hs-CRP ↓32.7%; P},
journal = {American Journal of Biochemistry and Biotechnology},
publisher = {Science Publications}
}